Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2010 - 2026)

Sunshine Biopharma (SBFM) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $27.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 4.31% year-over-year to $27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.5 million (up 1.98% YoY) and the FY2025 annual result came in at $30.1 million, down 1.57% from the prior year.
• Liabilities and Shareholders Equity retreated to $27.9 million in Q1 2026, from $30.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $42.0 million in Q2 2022 to a low of $13.4 million in Q1 2022.
• A 5-year average of $29.9 million and a median of $29.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 2210.92% — and 2023, when it slumped 32.34%.
• Tracing SBFM's Liabilities and Shareholders Equity over 5 years: stood at $29.2 million in 2022, then declined by 6.49% to $27.3 million in 2023, then gained by 11.75% to $30.6 million in 2024, then declined by 1.57% to $30.1 million in 2025, then fell by 7.14% to $27.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $27.9 million (Q1 2026), $30.1 million (Q4 2025), and $31.5 million (Q3 2025), per Business Quant data.